Advances in Coronary Stent Technology - Active Drug-Loaded Stent Surfaces for Prevention of Restenosis and Improvement of Biocompatibility

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|14|1|76-90

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.14, Iss.1, 2013-01, pp. : 76-90

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sirolimus-eluting stent superior for coronary artery restenosis prevention

By  

Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Dexamethasone and Restenosis After Coronary Stent Implantation: New Indication for an Old Drug?

By  

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 349-355

Bentham Science Publishers

Access to resources Recommend Favorite

Everolimus-eluting stent for prevention of restenosis

By  

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

A polymer-free, sirolimus-eluting stent is as effective as a standard, polymer-based, paclitaxel-eluting stent in the prevention of coronary artery restenosis

By  

Inpharma, Vol. 1, Iss. 1530, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Sirolimus-eluting stent reduces restenosis, coronary events

By  

Inpharma, Vol. 1, Iss. 1342, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite